Ligand id: 7470

Name: rufinamide

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: rufinamide

Structure and Physico-chemical Properties

2D Structure
Click here for structure editor
Calculated Physico-chemical Properties
Hydrogen bond acceptors 4
Hydrogen bond donors 1
Rotatable bonds 3
Topological polar surface area 73.8
Molecular weight 238.07
XLogP 0.89
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Rufinamide is used in combination with other medications to treat adults and children suffering epileptic seizures caused by Lennox-Gastaut syndrome. As of February 2015, approval was extended for this indication to include treatment of children from one year old, where previously only children >4 years could be treated with this drug.
Mechanism Of Action and Pharmacodynamic Effects
By blocking sodium channel alpha subunits, rufinamide prolongs the time that the channels remain in the inactive state. This stabilises the neuronal membranes and ultimately prevents the spread of seizure activity from an epileptogenic focus.
External links